CADTH Reimbursement Review - Provisional Funding Algorithm - Indication: Non-small cell lung cancer without actionable

The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. [...] CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceed ings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] Pembrolizumab January 3, 2020 pERC conditionally recommends the reimbursement of pembrolizumab in (Keytruda) combination with carboplatin and paclitaxel for the treatment of patients with metastatic squamous NSCLC, in adults with no prior systemic chemotherapy treatment for metastatic NSCLC if the following conditions are met: - cost-effectiveness being improved to an acceptable level. [...] Atezolizumab (Tecentriq) June 20, 2018 pERC recommends reimbursement of atezolizumab (Tecentriq) for patients with locally advanced or metastatic NSCLC and who have disease progression on or after cytotoxic chemotherapy only if the following conditions are met: - cost-effectiveness being improved to an acceptable level and - the drug plan cost of treatment with atezolizumab should not exceed the p.